Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Low Risk

Score: 25/100

Failure Rate

0.0%

0 terminated/withdrawn out of 3 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

100%

2 of 2 completed trials have results

Key Signals

1 recruiting2 with results

Enrollment Performance

Analytics

N/A
2(66.7%)
Phase 2
1(33.3%)
3Total
N/A(2)
Phase 2(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (3)

Showing 3 of 3 trials
NCT02559778Phase 2Recruiting

Pediatric Precision Laboratory Advanced Neuroblastoma Therapy

Role: collaborator

NCT02162732Not ApplicableCompleted

Molecular-Guided Therapy for Childhood Cancer

Role: collaborator

NCT01802567Not ApplicableCompleted

Molecular-Guided Therapy for Relapsed and Refractory Childhood Cancer

Role: collaborator

All 3 trials loaded